Park Ji Yeon, Lee Ji Young, Yi Seong Yoon
Department of Radiology, Inje University Ilsan Paik Hospital, Goyang 10380, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang 10380, Korea.
J Clin Med. 2022 Jan 3;11(1):238. doi: 10.3390/jcm11010238.
This study aimed to assess the incidence of axillary lymphadenopathy on ultrasound after COVID-19 vaccination and to investigate the factors affecting lymphadenopathy.
We evaluated patients who had received a COVID-19 vaccination within 12 weeks before an ultrasound examination between August and October 2021. The incidence of vaccine-related ipsilateral axillary lymphadenopathy was evaluated using ultrasound. Age, sex, presence of axillary symptoms, injection site, vaccine type, interval from vaccination, and dose were compared between the groups with and without axillary lymphadenopathy.
We included 413 patients, 202 (49%) of whom showed axillary lymphadenopathy on ultrasound after COVID-19 vaccination. Age, interval from vaccine, vaccine brand, vaccine type, dose, and symptom were significantly different between the lymphadenopathy and non-lymphadenopathy groups ( < 0.001), while the injection site and sex were not. Receiving an mRNA vaccine was the most important factor for axillary lymphadenopathy ( < 0.001), followed by intervals of 1-14 ( < 0.001) and 15-28 days ( < 0.001), younger age ( = 0.006), and first dose ( = 0.045).
COVID-19 vaccine-related axillary lymphadenopathy on ultrasound is common. mRNA type, an interval of 4 weeks, younger age, and first dose were the important factors. Breast clinicians should be well aware of these side effects when performing imaging examinations and provide accurate information to patients.
本研究旨在评估新冠病毒疫苗接种后超声检查腋窝淋巴结病的发生率，并调查影响淋巴结病的因素。
我们评估了在2021年8月至10月期间超声检查前12周内接种过新冠病毒疫苗的患者。使用超声评估疫苗相关同侧腋窝淋巴结病的发生率。比较有和没有腋窝淋巴结病的组之间的年龄、性别、腋窝症状的存在、注射部位、疫苗类型、接种间隔和剂量。
我们纳入了413名患者，其中202名（49%）在新冠病毒疫苗接种后超声检查显示腋窝淋巴结病。淋巴结病组和无淋巴结病组之间的年龄、接种间隔、疫苗品牌、疫苗类型、剂量和症状有显著差异（<0.001），而注射部位和性别没有差异。接种mRNA疫苗是腋窝淋巴结病的最重要因素（<0.001），其次是1 - 14天（<0.001）和15 - 28天的间隔（<0.001）、较年轻的年龄（=0.006）和第一剂（=0.045）。
新冠病毒疫苗接种后超声检查发现的与疫苗相关的腋窝淋巴结病很常见。mRNA类型、4周的间隔、较年轻的年龄和第一剂是重要因素。乳腺临床医生在进行影像学检查时应充分了解这些副作用，并向患者提供准确信息。
